Melanoma Cells News and Research

RSS

New insight into the response of human skin to radiation

Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer.

20 Nov 2008

Nanoparticle targets melanoma with siRNA

Research has shown that a particular receptor for the blood protein thrombin is overexpressed by highly metastatic melanoma cells.

20 Nov 2008

Nanoparticles target multiple cancer genes, shrink tumors more effectively

Nanoparticles filled with small interfering RNA (siRNA) molecules targeting two genes that trigger melanoma have shown that they can inhibit the development of melanoma, the most dangerous type of skin cancer.

27 Oct 2008

Scientists cure advanced skin cancer with body's own cells

Scientists in the U.S. are claiming they have cured advanced skin cancer by using the patient's own cells.

19 Jun 2008

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.

15 Jun 2008

New understanding of how a mole develops into melanoma

Researchers have discovered how a mole develops into melanoma by showing the interaction of two key proteins involved in 60-70 percent of tumors. The Penn State scientists also demonstrate that therapeutic targeting of these proteins is necessary for drugs to effectively treat this deadly form of cancer.

6 May 2008

New drug for melanoma riluzole shows promise

Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

16 Apr 2008

Skin product decreases malignant melanoma tumor growth according to study

A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

8 Apr 2008

Wistar Institute shares cell lines

Cell lines developed by scientists at The Wistar Institute in Philadelphia have recently been made available to researchers around the globe through the catalog collection at the Coriell Institute for Medical Research of Camden, N.J.

26 Mar 2008

Protein in embryonic stem cells control malignant tumor cells

A protein that governs development of human embryonic stem cells (hESCs) also inhibits the growth and spread of malignant melanoma, the deadliest skin cancer, Northwestern University researchers have discovered.

4 Mar 2008

Natural secretion marks difference between mole and melanoma

A protein naturally produced and secreted by the body can make the difference between your average mole and melanoma, which killed more than 8,000 people in the United States last year, reveals a new study in the February 8 issue of the journal Cell, a publication of Cell Press.

8 Feb 2008

Discovery of protein that stops the growth of melanomas

One might call it a tale of two melanocytes. Given the same genetic mutation, why does one melanocyte shut down growth and become a relatively benign mole, while another rages out of control and develops into deadly melanoma"

8 Feb 2008

Study shows that a key protein appears to enable spread of melanoma to the small intestine

A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center has shown that a receptor protein found on melanoma cells appears to facilitate the disease's spread to the small intestine.

5 Feb 2008

Bortezomib pushes cancer cells into overdrive, so that they self-destruct

University of Michigan Comprehensive Cancer Center researchers have discovered that bortezomib, a promising cancer drug, is able to strike a blow against melanoma tumor cells by revving up the action of a cancer-promoting gene.

21 Nov 2007

CD200 stifles anti-tumor immunity

The prognosis for individuals with metastatic melanoma (MM) is not good. Therapeutic strategies to enhance the immune response have some clinical benefit; however, most patients eventually succumb to progressive disease, in part because their immune cells known as dendritic cells (DCs) fail to sustain an effective antitumor T cell immune response.

16 Nov 2007

Synthetic compound promotes death of lung-cancer cells, tumors

Human lung-cancer tumors grown in mice have been shown to regress or disappear when treated with a synthetic compound that mimics the action of a naturally occurring "death-promoting" protein found in cells, researchers at UT Southwestern Medical Center report.

13 Nov 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007